modelPKPG_1C_Gentamicin
Extends from Examples.PKOneCompartmentModel.
Information
Pharmacogenomic (PGx) models seeks to quantify how inherited genetic variation modulates both drug pharmacokinetics and pharmacodynamics.
Example diagram mode of 1-compartment PK model of gentamicine modified by PGx influence on clearance rate. Clearance rate can be influenced by CYP2C19 genotype and SLC22A2 genotype. The
scale factors in the PGx modification of PK model is just an example estimation of influence on renal clearance. Correct values should be fit to specific published experimental results.
Simulation of PKPGx model of gentamicine with normal SLC22A2 alleles compared to allele
’808T’ with altered clearance.
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Types.MassConcentration | MIC | 0.002 | Minimal inhibitory concentration |
| Types.MassConcentration | C_tox_peak | 0.012 | Peak toxicity concentration |
| Types.MassConcentration | C_tox_valley | 0.0021 | Peak toxicity concentration |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Sources.SingleDose | singleDose (from PKOneCompartmentModel) | ||
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PKOneCompartmentModel) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PKOneCompartmentModel) | ||
| Sources.ClearanceConst | elimClearance | ||
| Pharmacolibrary.Pharmacogenomics.Modifiers.ClearanceModifierComponent | clearanceModifierComponent | ||
| Pharmacolibrary.Pharmacogenomics.PGx.GenotypePhenotypeComponent | SLC22A2 | ||
| Pharmacolibrary.Pharmacogenomics.PGx.GenotypePhenotypeComponent | CYP2C19 | ||
| Pharmacolibrary.Pharmacogenomics.Modifiers.ClearanceModifierComponent | clearanceModifierComponent1 |